Drug Type Bispecific antibody |
Synonyms- |
Target |
Action modulators |
Mechanism CD40 modulators(Tumor necrosis factor receptor superfamily member 5 modulators), PDL1 modulators(Programmed death-ligand 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | United States | 28 May 2020 |